Interest in MUC1-based cancer immunotherapy stems from this marker's aberrant glycosylation in tumor cells due to truncated, highly sialylated O-glycans that occur at up to five potential sites on each of MUC1's 20 amino acid tandem repeat sequence (Figure 5A). Here, MUC1 is linked to cancer.